Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from compositeae
Reexamination Certificate
2008-04-29
2008-04-29
Flood, Michele (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from compositeae
C424S757000, C424S773000, C424S774000, C514S885000
Reexamination Certificate
active
11270649
ABSTRACT:
This invention relates to compositions for the treatment of acquired immunodeficiency diseases, especially human immunodeficiency virus (HIV), and its simian and feline counterparts (simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV)), and to methods for their use.
REFERENCES:
patent: 4659558 (1987-04-01), Urquhart et al.
patent: 4810499 (1989-03-01), Nuwayser
patent: 5055297 (1991-10-01), Fujimaki et al.
patent: 5204101 (1993-04-01), Stubblefield
patent: 5438040 (1995-08-01), Ekwiribe
patent: 5629020 (1997-05-01), Leone-Bay et al.
patent: 5641511 (1997-06-01), Kuhrts
patent: 5648209 (1997-07-01), Avrameas et al.
patent: 5654000 (1997-08-01), Poli et al.
patent: 5665592 (1997-09-01), Tompkins et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5690954 (1997-11-01), Illum
patent: 5691183 (1997-11-01), Franzusoff et al.
patent: 5759566 (1998-06-01), Poli et al.
patent: 5766633 (1998-06-01), Milstein et al.
patent: 5783212 (1998-07-01), Fassihi et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5849331 (1998-12-01), Ducheyne et al.
patent: 5879712 (1999-03-01), Bomberger et al.
patent: 5935601 (1999-08-01), Leone-Bay et al.
patent: 6002961 (1999-12-01), Mitragotri et al.
patent: 6017318 (2000-01-01), Gauthier et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6018678 (2000-01-01), Mitragotri et al.
patent: 6041253 (2000-03-01), Kost et al.
patent: 6072041 (2000-06-01), Davis et al.
patent: 6090389 (2000-07-01), Chen
patent: 6228608 (2001-05-01), Young et al.
patent: 6254872 (2001-07-01), Yamamoto
patent: 62048619 (1987-03-01), None
patent: 02053730 (1990-02-01), None
patent: 0441278 (1991-08-01), None
patent: 09188621 (1997-07-01), None
Ahn, B.Z. et al., “Inhibitory effect of bupleuri radix saponins on adhesion of some solid tumor cells and relation to hemolytic action: screening of 232 herbal drugs for anti-cell adhesion,” Planta Med. Apr. 1998;64(3):220-4.
Bogers, W.M. et al., “Developments in preclinical AIDS vaccine efficacy models,” AIDS. 2000;14 Suppl 3:S141-51.
Brunner, D., et al., “Infection of Peritoneal Macrophages In Vitro and In Vivo with Feline Immunodeficiency Virus,” J. Virol. 63:5483 (1989).
Chaisson, R.E., “HIV Becomes World's Leading Infectious Cause Of Death,” Hopkins HIV Rep. Jul. 1999;11(4):1.
Chen, X. et al., “Therapeutic Effect Of Radix Astragali On Hypoxia Pulmonary Hypertension In Rats,” Zhongguo Zhong Yao Za Zhi. Jul. 1997;22(7):432-4.
Cohn, J.A., “Virology, Immunology, And Natural History Of HIV Infection,” J. Nurse Midwifery Sep.-Oct. 1989;34(5):242-52.
D'Souza, M.P., et al., “Current Evidence And Future Directions For Targeting HIV Entry,” JAMA, 284, No. 2, 215-222.
Ebata, N. et al., “Saponins From The Root Of Bupleurum Falcatum,”0 Phytochemistry. 1996 41(3):895-901.
Friend, SCE et al., “Feline Immunodeficiency Virus: Prevalence, Disease Associations and Isolation,” Aust. Vet J., 67:237 (1990).
Gardner, M., et al. “Animal Models of AIDS,” FASEB Journal 3: 2593 (1989).
Gottlieb, S., “Gap in HIV Infection Widens,” BMJ 1998;317;11.
Harbour et al., “Isolation of a T-Lymphotropic Lentivirus from a Persistently Leucopenic Domesti Cat,” Vet Rec, 122:84 (1988).
Hayashi, T., “Studies On Crude Drugs Originated From Gentianaceous Plants. I. Determination Of Gentiopicroside, The Bitter Principle Of Gentianae Radix And Gentianae Scabrae Radix,” Yakugaku Zasshi. Mar. 1976;96(3):356-61.
Hirsch VM, et al., “Pathogenic Diversity Of Simian Immunodeficiency Viruses,” Virus Res. May 1994;32(2):183-203.
Hu, C.Q. et al., “Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids,” J Nat Prod. Jan. 1994;57(1):42-51.
Hu, S. et al., “Influence of medicinal herbs on phagocytosis by bovine neutrophils,” Zentralbl Veterinarmed A. Oct. 1992;39(8):593-9.
Ishida et al., “Detection Of Feline T-Lymphotropic Lentivirus (FTLV) Infection In Japanese Domestic Cats,” Jpn J Vet Sci, 50:39 (1988).
Izumi, S. et al., “Wide Range Of Molecular Weight Distribution Of Mitogenic Substance(S) In The Hot Water Extract Of A Chinese Herbal Medicine, Bupleurum Chinense,” Biol Pharm Bull. Jul. 1997;20(7):759-64.
Johnston, et al., “Present Status and Future Prospects for HIV Therapies,” 1993, Science 260, 1286-1293.
Kajimura, K. et al., “Protective Effect Of Astragali Radix By Oral Administration Against Japanese Encephalitis Virus Infection In Mice,” Biol Pharm Bull. Sep. 1996;19(9):1166-1169.
Kanbe K., et al., “A CXC Chemokine Receptor, CXCR5/BLR1, Is A Novel And Specific Co-Receptor For Human Immunodeficiency Virus Type 2,” Virology Dec. 20, 1999;265(2):264-73.
Kang, J.J. et al., “Modulation Of Microsomal Cytochrome P450 By Scutellariae Radix And Gentianae Scabrae Radix In Rat Liver,” Am J Chin Med. 1996;24(1):19-29.
Kim, H.M. et al., “Magnoliae Flos Inhibits Mast Cell-Dependent Immediate-Type Allergic Reactions,” Pharmacol Res. Feb. 1999;39(2):107-11.
Kimura, I. et al., “Inhibitory Effects Of Magnoshinin And Magnosalin, Compounds From “Shin-I” (Flos Magnoliae), On The Competence and Progression Phases In Proliferation Of Subcultured Rat Aortic Endothelial Cells,” Jpn J Pharmacol. Sep. 1992;60(1):59-62.
Kimura, I. et al., “Neuromuscular Blocking Action Of Alkaloids From A Japanese Crude Drug “Shin-L” (Flos Magnoliae) In Frog Skeletal Muscle,” Planta Med. May 1983;48(1):43-7.
Kimura, M. et al., “Anti-Inflammatory Effect Of Neolignans Newly Isolated From The Crude Drug “SHIN-I” (Flos Magnoliae),” Planta Med. Aug. 1985;(4):291-3.
Kimura, M. et al., “Selective Inhibition By Magnosalin And Magnoshinin, Compounds From “Shin-I” (Flos Magnoliae), Of Adjuvant-Induced Angiogenesis And Granuloma Formation In The Mouse Pouch,” Agents Actions Suppl. 1991;32:197-201.
Kobayashi, S. et al., “Inhibitory Effect Of Magnosalin Derived From Flos Magnoliae On Tube Formation Of Rat Vascular Endothelial Cells During The Angiogenic Process,” Biol Pharm Bull. Oct. 1996;19(10):1304-6.
Kobayashi, S. et al., “Inhibitory Effects Of Anti-Rheumatic Drugs Containing Magnosalin, A Compound From ‘Shin-I’ (Flos Magnoliae), On The Proliferation Of Synovial Cells In Rheumatoid Arthritis Models,” Immunopharmacology. May 1998;39(2):139-47.
Kok, L.D. et al., “Activation Of The Anti-Tumor Effector Cells By Radix Bupleuri,” Immunopharmacology. Jun. 1995;30(1):79-87.
Kurashige, S. et al., “Effects of astragali radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N′-butanolnitrosoamine,” Cancer Invest. 1999;17(1):30-5.
Li, G. et al., “Preparation Method And Quality Control Of Compound Daphne Injection,” Zhongguo Zhong Yao Za Zhi. Nov. 1992;17(11):664-5, 702.
Liao, J.F. et al., “Evaluation With Receptor Binding Assay On The Water Extracts Of Ten CNS-Active Chinese Herbal Drugs,” Proc Natl Sci Counc Repub China B. Jul. 1995;19(3):151-8.
Lin, C.C. et al., “Anatomical And Histological Studies Of Bupleuri Radix,” Am J Chin Med. 1991;19(3-4):265-74).
Luckner, M. et al., “Suggestions For The Drug Section Of The DAB 7. 5. Radix Gentianae,” Pharmazie. Jan. 1965;20(1):16-9).
Luo, J.P. et al., “Morphological And Histological Studies Of The Chinese Drug Longdan, Radix Gentianae,” Yao Xue Xue Bao. Aug. 1987;22(8):619-36.
Martinon, O., et al., “Le Virus de l'Immunodéfience Féline,” Vet Res 1993;24(2):151-8.
Nagasawa, M. et al., “The Geographical Variation Of Essential Oils Of Flos Magnoliae,” Yakugaku Zasshi. Apr. 1969;89(4):454
Chinese Herbal USA Inc.
Flood Michele
LandOfFree
Compositions for the treatment of acquired immunodeficiency... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for the treatment of acquired immunodeficiency..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the treatment of acquired immunodeficiency... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3929785